


PRODUCT INFORMATION

(±)-Atenolol

Item No. 17250

CAS Registry No.: 29122-68-7
Formal Name: 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-benzeneacetamide
Synonyms: (R,S)-Atenolol, Duraatenol, ICI 66082
MF: C₁₄H₂₂N₂O₃
FW: 266.3
Purity: ≥98%
UV/Vis.: λ_{max}: 227, 277, 283 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

(±)-Atenolol is supplied as a crystalline solid. A stock solution may be made by dissolving the (±)-atenolol in the solvent of choice, which should be purged with an inert gas. (±)-Atenolol is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of (±)-atenolol in these solvents is approximately 5, 15, and 20 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of (±)-atenolol can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of (±)-atenolol in PBS, pH 7.2, is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

(±)-Atenolol is an antagonist of the β₁-adrenergic receptor (β₁-AR; K_i = 1.14 μM).¹ It is selective for β₁-ARs over β₂-ARs (K_i = 48.7 μM). (±)-Atenolol (200 mg/kg per day) delays the onset of hypertension in spontaneously hypertensive rats.² Formulations containing atenolol have been used in the treatment of high blood pressure.

References

1. Golf, S., Bjornerheim, R., Erichsen, A., *et al.* Relative selectivity of different β-adrenoceptor antagonists for human heart β₁- and β₂-receptor subtypes assayed by a radioligand binding technique. *Scand. J. Clin. Lab. Invest.* **47(7)**, 719-723 (1987).
2. Richer, C., Boissier, J.R., and Giudicelli, J.F. Chronic atenolol treatment and hypertension development in spontaneously hypertensive rats. *Eur. J. Pharmacol.* **47(4)**, 393-400 (1978).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/27/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM